UK Regulatory Insight: Cambridge Establishes New Pathway for Psychedelic Medical Research and NHS Integration

The Cambridge Psychedelic Research Group (CPRG) has rapidly established itself as a significant player in the UK's psychedelic research landscape, having secured its Home Office licence in 2024 and officially launching in March 2025. One year into its operations, CPRG is conducting multiple clinical trials and actively developing group therapy models aimed at making psychedelic-assisted treatments more accessible and scalable through the National Health Service (NHS). This initiative, a partnership between the University of Cambridge and two NHS trusts, marks the creation of the first legal pathway for psychedelic-assisted treatments in the East of England, signaling a growing institutional and regulatory framework for medical psychedelics within the UK.